Cross talk between toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 4, 2013, Pages 723-730

  Shirai, Yusaku ^a   Yoshiji, Hitoshi ^a   Noguchi, Ryuichi ^a   Kaji, Kosuke ^a   Aihara, Yosuke ^a   Douhara, Akitoshi ^a   Moriya, Kei ^a   Namisaki, Tadashi ^a   Kawaratani, Hideto ^a   Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II; Lipopolysaccharide; Liver fibrosis; Non alcoholic steatohepatitis; Toll like receptor 4

Indexed keywords

ANGIOTENSIN II; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOSARTAN; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE COURSE; IN VITRO STUDY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL;

EID: 84875592099     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12112     Document Type: Article

References (42)

1. Mencine A, Kluwe J, Schwabe RF. Toll-like receptors as targets in chronic liver disease. Gut 2009; 58: 704-720.
2. Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrosis. Fibrogenesis Tissue Repair 2010; 3: 21.
3. Soares JB, Pimental-Nunes P, Roncon-Albuguerque R etal. The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases. Hepatol. Int. 2010; 4: 659-672.
4. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology 2006; 130: 1886-1900.
5. Lin RS, Lee FY, Lee SD etal. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver disease, presence of esophageal varices, and hyperdynamic circulation. J. Hepatol. 1995; 22: 165-172.
6. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-787.
7. Su GL, Klein RD, Aminlari A etal. Kupffer cell activation by lipopolysaccharide in rats: role for lipopolysaccharide binding protein and toll-like receptor 4. Hepatology 2000; 31: 932-936.
8. Paik YH, Schwabe RF, Bataller R etal. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003; 37: 1043-1055.
9. Seki E, De Minicis S, Osterreicher CH etal. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 2007; 13: 1324-1332.
10. Helmy A, Jalan R, Newby DE etal. Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology 2000; 118: 565-572.
11. Asbert M, Jimenez W, Gaya J etal. Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin. J. Hepatol. 1992; 15: 179-183.
12. Yoshiji H, Yoshii J, Ikenaka Y etal. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J. Hepatol. 2002; 37: 22-30.
13. Yoshiji H, Kuriyama S, Noguchi R etal. Angiotensin-I-converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr. Cancer Drug Targets 2004; 4: 555-567.
14. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiotenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002; 23: 348-356.
15. Tharaux PL, Chatziantoniou C, Fakhouri F etal. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ER kinase pathway. Hypertension 2000; 36: 330-336.
16. Marshall RP, McAnulty RJ, Laurent GJ. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor. Am. J. Respir. Crit. Care Med. 2000; 161: 1999-2004.
17. Kagami S, Border WA, Miller DE etal. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 1994; 93: 2431-2437.
18. Zhang YJ, Yang XS, Wu PS etal. Expression of AT(1a) mRNA in rat hepatic stellate cells and its effects on cell growth collagen production. Chin. Med. J. 2004; 117: 772-774.
19. Hirose A, Ono M, Saibara T etal. Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcohoric steatohepatitis. Hepatology 2007; 45: 1375-1381.
20. Yoshiji H, Noguchi R, Ikenaka Y etal. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res. Notes 2009; 2: 70.
21. Yokohama S, Yoneda M, Handa M etal. Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis. Hepatology 2004; 40: 1222-1225.
22. Wu J, Yang X, Zhang YF etal. Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD 40 expression in rat peritoneal mesotherial cells. Inflamm. Res. 2009; 58: 473-482.
23. Wolf G, Bohlender J, Bondeva T etal. Angiotensin II upregulates toll-like receptor 4 on mesangial cells. J. Am. Soc. Nephrol. 2006; 17: 1585-1593.
24. Ludwig J, Viggano TR, McGill DB etal. Nonalcoholic Steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease. Mayo Clin. Proc. 1980; 55: 434-438.
25. Zen Y, Katayanagi K, Tsuneyama K etal. Hepatocellular carcinoma arising in non-alcoholic steatohepatitis. Pathol. Int. 2001; 51: 127-131.
26. Shimada M, Hashimoto E, Taniai M etal. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J. Hepatol. 2002; 37: 154-160.
27. Bugianesi E, Leone N, Vanni E etal. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-140.
28. Yang SQ, Lin HZ, Lane MD etal. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc. Natl. Acad. Sci. U. S. A. 1997; 94: 2557-2562.
29. Li Z, Yang S, Lin H etal. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-350.
30. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver inter-actions and possible role for probiotics. J. Hepatol. 2003; 38: 681-687.
31. Livera CA, Adegboyega P, van Rooijen N etal. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 2007; 47: 571-579.
32. Yoshiji H, Kuriyama S, Yoshii J etal. Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis. Gut 2003; 52: 1347-1354.
33. Yoshiji H, Kuriyama S, Yoshii J etal. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 2001; 34: 745-750.
34. Weiskirchen R, Gressner AM. Isolation and culture of hepatic stellate cells. Methods Mol. Med. 2005; 117: 99-113.
35. Rockey DC, Boyles JK, Gabbiani G, Friedman SL. Rat hepatic lipocytes express smooth muscle actin upon activation in vivo and in culture. J. Submicrosc. Cytol. Pathol. 1992; 24: 193-203.
36. Yoshiji H, Kuriyama S, Yoshii J etal. Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 2002; 35: 834-842.
37. Kaji K, Yoshiji H, Kitade M etal. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 2011; 300: 1094-1104.
38. Kawaratani H, Tsujimoto T, Kitazawa T etal. Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet. World J. Gastroenterol. 2008; 14: 6655-6661.
39. Adachi Y, Bradford BU, Gao W etal. Inactivation of Kupffer cells prevents early alcoholic-induced liver injury. Hepatology 1994; 20: 453-460.
40. Ji Y, Liu J, Wang Z etal. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell. Physiol. Biochem. 2009; 23: 265-276.
41. Wang WW, Yang XS, Li X etal. Changes in the expression of angiotensin II type 1 receptor in the development of liver fibrosis. Chin. J. Dig. Dis. 2004; 5: 118-122.
42. Roger T, Miconnet I, Schiesser AL etal. Critical role of Ets, AP1 and GATA-like transcription factors in regulating mouse Toll-like receptor 4 (Tlr4) gene expression. Biochem. J. 2005; 387: 355-365.